MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ecco-jcc/jjac086

Медицинская библиотека · Journal of Crohn's & colitis · 2022

Safety of Ustekinumab and Vedolizumab During Pregnancy-Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study.

Mitrova Katarina, Pipek Barbora, Bortlik Martin, Bouchner Ludek, Brezina Jan, Douda Tomas, Drasar Tomas, Klvana Pavel, Kohout Pavel, Leksa Vaclav, Minarikova Petra, Novotny Ales, Svoboda Pavel, Skorpik Jan, Ulbrych Jan, Veinfurt Marek, Zborilova Blanka, Lukas Milan, Duricova Dana, Czech IBD Working Group

Наблюдательное исследованиеМногоцентровое исследованиеСтатьяПеревод в очереди

Аннотация

BACKGROUND AND AIMS: Evidence on the safety of newer biologics during pregnancy is limited. We aimed to assess the safety of ustekinumab and vedolizumab treatment during gestation on pregnancy and infant outcome. Furthermore, we evaluated the placental transfer of these agents.

METHODS

We performed a prospective, multicentre, observational study in consecutive women with inflammatory bowel disease exposed to ustekinumab or vedolizumab 2 months prior to conception or during pregnancy. Pregnancy, neonatal, and infant outcomes were evaluated and compared with the anti-tumour necrosis factor [TNF]-exposed control group. Drug levels were assessed in maternal and cord blood at delivery.

RESULTS

We included 54 and 39 pregnancies exposed to ustekinumab and vedolizumab, respectively. In the ustekinumab group, 43 [79.9%] resulted in live births, and 11 [20.4%] led to spontaneous abortion. Thirty-five [89.7%] pregnancies on vedolizumab ended in a live birth, two [5.1%] in spontaneous, and two [5.1%] in therapeutic abortion. No significant difference in pregnancy outcome between either the vedolizumab or the ustekinumab group and controls was observed [p >0.05]. Similarly, there was no negative safety signal in the postnatal outcome of exposed children regarding growth, psychomotor development, and risk of allergy/atopy or infectious complications. The median infant-to-maternal ratio of ustekinumab levels was 1.67 and it was 0.59 in vedolizumab.

CONCLUSIONS

Use of ustekinumab and vedolizumab in pregnancy seems to be safe, with favuorable pregnancy and postnatal infant outcomes. Placental transfer differed between these two drugs, with ustekinumab having similar and vedolizumab having inverse infant-to-maternal ratio of drug levels compared with anti-TNF preparations.

Для цитирования: Mitrova Katarina, Pipek Barbora, Bortlik Martin, Bouchner Ludek, Brezina Jan, Douda Tomas, Drasar Tomas, Klvana Pavel, Kohout Pavel, Leksa Vaclav, Minarikova Petra, Novotny Ales, Svoboda Pavel, Skorpik Jan, Ulbrych Jan, Veinfurt Marek, Zborilova Blanka, Lukas Milan, Duricova Dana, Czech IBD Working Group. Safety of Ustekinumab and Vedolizumab During Pregnancy-Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study.. Journal of Crohn's & colitis. 2022. DOI: 10.1093/ecco-jcc/jjac086.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.